Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4235 | Virtual Group Exercise Wiki | 1.00 |
| drug2638 | Nutrition Consult and Protein Supplementation Wiki | 1.00 |
| drug2314 | Medication Review Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The coronavirus disease 2019 (COVID-19) pandemic is keeping people apart, which can take a toll on physical and mental health. Many healthcare professionals are concerned vulnerable seniors may become deconditioned, which substantially increases risk of health complications and need for hospitalization. To address the immediate impact of COVID-19 policies (i.e., physical distancing, reduced access to care), the GERAS Frailty Rehabilitation model will be adapted to be delivered remotely in the homes of vulnerable seniors. The investigators' aim is to understand how to best build resilience among vulnerable seniors in the community through at-home rehabilitation services (socialization, exercise, nutrition, and medication support).
Description: Assessed by the 5x Sit-to-Stand (time to complete). Faster times to complete indicate better performance.
Measure: Change in Physical Function Time: Baseline and 12 Weeks Post-InterventionDescription: Assessed by the Depression Anxiety Stress Scale (DASS-21). Higher scores indicate greater risk of depression, anxiety and stress [depression, anxiety, stress subscores range 0-21].
Measure: Change in Mental Health Time: Baseline and 12 Weeks Post-InterventionDescription: Assessed by the SARC-F - Self-reported strength, assistance with walking, rising from a chair, climbing stairs and falls. Higher scores indicate greater level of sarcopenia [range 0-10].
Measure: Change in Sarcopenia Time: Baseline and 12 Weeks Post-InterventionDescription: Assessed by the Fit-Frailty Index. Higher scores indicate greater degree of frailty [range 0-1].
Measure: Change in Frailty Time: Baseline and 12 Weeks Post-InterventionDescription: Balance confidence will be assessed using the Activities-specific Balance Confidence Scale (ABCs). Higher scores indicate greater balance confidence [range 0-100].
Measure: Change in Self-Efficacy Time: Baseline and 12 Weeks Post-InterventionDescription: Assessed by the interRAI Community Rehab Assessment - Self-Report
Measure: Self-Reported Change in Function, Health and Well-Being Time: Baseline and 12 Weeks Post-InterventionDescription: Assessed by the interRAI Community Rehab Assessment - Clinician-Completed
Measure: Clinician-Reported Change in Function, Health and Well-Being Time: Baseline and 12 Weeks Post-InterventionDescription: Assessed by the Borg Rate of Perceived Exertion after exercise. Higher scores indicate greater level of exertion [range 6-20].
Measure: Change in Fitness Time: Weekly up to 12 weeksDescription: Assessed using a program questionnaire in accordance with the Kirkpatrick 5-Level Evaluation Model. Scores will be on a 5-point Likert scale ranging from "Strongly Disagree" to "Strongly Agree".
Measure: Program Satisfaction Time: 12 Weeks Post-InterventionDescription: Number of emergency room visits will be recorded. Higher number of emergency room visits indicates higher healthcare utilization.
Measure: Change in Emergency Room Visits Time: Baseline and 12 Weeks Post-InterventionDescription: Number of hospitalizations will be recorded. Higher number of hospitalizations indicates higher healthcare utilization.
Measure: Change in Hospitalizations Time: Baseline and 12 Weeks Post-InterventionDescription: Number of calls to 911 will be recorded. Higher number of calls indicates higher healthcare utilization.
Measure: Change in Number of Calls to 911 Time: Baseline and 12 Weeks Post-InterventionDescription: Assessed by the number of individuals who participated. Target reach is 70 participants.
Measure: Feasibility Outcome #1 - Reach of intervention Time: 12 Weeks Post-InterventionDescription: Assessed by number of referral sites. Target is 5 referral sites.
Measure: Feasibility Outcome #2 - Adoption of the Intervention Time: 12 Weeks Post-InterventionDescription: Assessed by the number of individuals who completed the intervention. Higher number of individuals completing the study indicates greater success in implementation.
Measure: Feasibility Outcome #3 - Implementation of the Intervention Time: 12 Weeks Post-InterventionDescription: Assessed by the number of referral sites continuing with a second cohort. Greater number of referral sites continuing with a second cohort indicates greater maintenance.
Measure: Feasibility Outcome #4 - Maintenance of the Intervention Time: 12 Weeks Post-InterventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports